Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1689433 | 0.98 | CYP1A2 (0.51) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL22065483 | 0.87 | CYP1A2 (0.44) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL8973710 | 0.83 | CA12 (0.40) | CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL20025625 | 0.82 | MIF (0.52) | MAOAMAOBMIFALDH1A1TRPA1 | |
| SCHEMBL10592677 | 0.81 | MIF (0.47) | CYP1A2CYP2D6SIGMAR1MAOAMAOB | |
| SCHEMBL3830223 | 0.78 | CYP1A2 (0.82) | CYP1A2CYP2D6ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2046670 | 0.78 | MIF (0.65) | SIGMAR1MIFALDH1A1TRPA1CYP3A4 | |
| SCHEMBL11322654 | 0.77 | KCNH2 (0.43) | CYP1A2CYP2D6SIGMAR1MIFALDH1A1 | |
| SCHEMBL6238480 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL21675912 | 0.74 | MIF (0.59) | CYP2D6TAAR1MIFALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095782-A1 | NEW METHOD FOR PREPARING 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)BENZENAMINE | Esteve Química, S.A. (ES) | 2016-11-23 | — | — | EP | claimed |
| US-20110275077-A1 | Oligonucleotide-Coated Affinity Membranes and Uses Thereof | JAMES WILLIAM | 2011-11-10 | — | — | US | claimed |
| WO-2010081114-A2 | OLIGONUCLEOTIDE-COATED AFFINITY MEMBRANES AND USES THEREOF | 20/20 GENESYSTEMS, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| EP-1305064-B1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS INC (US) | 2008-04-23 | — | — | EP | claimed |
| US-RE37160-E1 | COUPLING A HYDROXYPHENYL CARBOXYLIC ACID WITH AN L-TYROSINE ESTER IN A WATER-MISCIBLE ORGANIC REACTION SOLVENT CONTAINING A CARBODIIMIDE CAPABLE OF FORMING A WATER-SOLVENT UREA BY-PRODUCT | RUTGERS, THE STATE UNIVERSITY | 2001-05-01 | — | — | US | claimed |
| EP-0824513-B1 | IMPROVED SYNTHESIS OF TYROSINE-DERIVED DIPHENOL MONOMERS | UNIV RUTGERS (US) | 2000-07-19 | — | — | EP | claimed |
| US-5834273-A | URICASE MODIFIED BY REACTING WITH POLYAMINO ACID CONTAINING GLUTAMIC ACID OR ASPARTIC ACID RESIDUES | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-10 | — | — | US | claimed |
| EP-0824513-A1 | IMPROVED SYNTHESIS OF TYROSINE-DERIVED DIPHENOL MONOMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-02-25 | — | — | EP | claimed |
| EP-0824513-A4 | — | — | 1998-02-25 | — | — | EP | claimed |
| US-5587507-A | PURIFICATION BY FORMING WATER SOLUBLE UREA BY-PRODUCT | RUTGERS, THE STATE UNIVERSITY (US) | 1996-12-24 | — | — | US | claimed |
| WO-1996030331-A1 | IMPROVED SYNTHESIS OF TYROSINE-DERIVED DIPHENOL MONOMERS | RUTGERS, THE STATE UNIVERSITY (US) | 1996-10-03 | — | — | WO | claimed |
| EP-3095782-A1 | NEW METHOD FOR PREPARING 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)BENZENAMINE | Esteve Química, S.A. (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-20110275077-A1 | Oligonucleotide-Coated Affinity Membranes and Uses Thereof | JAMES WILLIAM | 2011-11-10 | — | — | US | disclosed |
| EP-2023970-B1 | BIOACTIVE POLYMERS FOR IMPARTING BIOACTIVE CHARACTER TO HYDROPHOBIC MEDICAL ARTICLE SURFACES | BOSTON SCIENT LTD (BB) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010081114-A2 | OLIGONUCLEOTIDE-COATED AFFINITY MEMBRANES AND USES THEREOF | 20/20 GENESYSTEMS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0364980-B1 | COLONY STIMULATING FACTOR-GELATIN CONJUGATE | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0506431-A1 | Modified enzyme | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1992-09-30 | — | — | EP | disclosed |
| EP-0409117-A1 | Silver halide photographic material | KONICA CORPORATION (JP) | 1991-01-23 | — | — | EP | disclosed |
| EP-0364980-A2 | Colony stimulating factor-gelatin conjugate | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-04-25 | — | — | EP | disclosed |
| EP-0346087-A2 | Hybrid antibody and process for the production thereof | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275077-A1 | Oligonucleotide-Coated Affinity Membranes and Uses Thereof | CD2BP2, CPSF6, CPSF1 | CYP1A2 4873/4885CYP2D6 4793/4885SIGMAR1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.